Mark Tarr Sells 150,000 Shares of Encompass Health (NYSE:EHC) Stock

Encompass Health Corporation (NYSE:EHC) CEO Mark Tarr sold 150,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total value of $16,746,000.00. Following the completion of the transaction, the chief executive officer owned 377,070 shares in the company, valued at $42,096,094.80. This represents a 28.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Encompass Health Price Performance

NYSE EHC opened at $110.02 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.08 and a debt-to-equity ratio of 0.76. The company has a market cap of $11.07 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 2.13 and a beta of 0.73. Encompass Health Corporation has a 52 week low of $92.53 and a 52 week high of $127.99. The firm’s 50-day simple moving average is $103.93 and its two-hundred day simple moving average is $114.49.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.17. The company had revenue of $3.09 billion for the quarter, compared to analyst estimates of $1.54 billion. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.17 earnings per share. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Research analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

A number of large investors have recently modified their holdings of the company. Tectonic Advisors LLC grew its position in Encompass Health by 1.6% during the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock valued at $678,000 after acquiring an additional 82 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Encompass Health by 23.0% in the 3rd quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock valued at $57,000 after purchasing an additional 84 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock valued at $453,000 after purchasing an additional 88 shares during the last quarter. Natural Investments LLC raised its position in Encompass Health by 1.2% in the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock worth $991,000 after purchasing an additional 89 shares during the period. Finally, Allworth Financial LP lifted its stake in Encompass Health by 14.7% in the third quarter. Allworth Financial LP now owns 701 shares of the company’s stock worth $89,000 after purchasing an additional 90 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EHC shares. Zacks Research lowered shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Barclays upped their price target on shares of Encompass Health from $150.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Raymond James Financial raised Encompass Health to a “strong-buy” rating in a research note on Friday, October 31st. Finally, Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $143.29.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.